Prevalence of screening for Lynch syndrome varies

Prevalence of screening for lynch syndrome varies
Screening for Lynch syndrome, the most common form of inherited colorectal cancer, after a colorectal cancer diagnosis is common at comprehensive cancer centers but not community hospitals, according to a study published online Feb. 21 in the Journal of Clinical Oncology.

(HealthDay) -- Screening for Lynch syndrome, the most common form of inherited colorectal cancer, after a colorectal cancer diagnosis is common at comprehensive cancer centers but not community hospitals, according to a study published online Feb. 21 in the Journal of Clinical Oncology.

To describe prevalent practices regarding immunohistochemistry (IHC) and microsatellite instability (MSI) reflex testing for Lynch syndrome after a colorectal , Laura C. Beamer, Ph.D., from City of Hope in Duarte, Calif., and colleagues surveyed 39 National Cancer Institute-designated Comprehensive Cancer Centers (NCI-CCCs), 50 American College of Surgeons-accredited Community Hospital Comprehensive Cancer Programs (COMPs), and 50 Community Hospital Cancer Programs (CHCPs). The overall response rate for all centers and programs was 50 percent.

The researchers found that reflex testing was conducted by 71 percent of NCI-CCCs, 36 percent of COMPs, and 15 percent of CHCPs. Of these, 48 percent used IHC, 14 percent used MSI, and 38 percent used both. None of the institutions required written consent, one used a presurgical information packet, and four offered an opt-out option.

"Although most NCI-CCCs use reflex IHC/MSI to screen for Lynch syndrome, this practice is not well-adopted by community hospitals," Beamer and colleagues conclude. "These findings may indicate an emerging standard of care and diffusion from NCI-CCCs to community cancer programs."

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.